iBio sees 98% Activin E inhibition from single IBIO-610 dose

iBio reported that a single dose of IBIO-610 achieved near-complete suppression of active Activin E levels in obese NHPs for eight weeks. This data supports a potential long-acting antibody therapy approach for obesity and enhances the outlook for combination treatments with semaglutide.